Feltl and Company reiterated its IDEXX Laboratories IDXX Hold rating and increased its price target from $87.50 to $90 in a research report published today.
In the report, Feltl and Company stated, "While we believe IDEXX is positioned well for veterinary market recovery, it currently trades near the high end of its historical multiples. We would like to see additional improvement in the veterinary market, an accelerating replacement cycle, or more attractive prices before becoming more positive on the shares."
Shares of IDEXX Laboratories were trading at $85.19 at the time of posting, down 1.45% from Friday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in